Bayabao, Alaizah D.

HRN: 21-95-47  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/12/2022
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
10/12/2022
10/18/2022
IV
60mg
Q12
Hypovolemic Shock Secondary To Acute Gastroenteritis
Waiting Final Action 
10/12/2022
CEFTRIAXONE 1G (VIAL)
10/12/2022
10/18/2022
IV
800mg
Od
Hypovolemic Shock Secondary To Acute Gastroenteritisl
Waiting Final Action 
10/12/2022
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
10/14/2022
10/20/2022
IVT
400mg
Q6hrs
Hif; Status Epilepticus
Waiting Final Action 
10/15/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
10/15/2022
10/21/2022
IV
130mg
Q8
Septic Shock Secondary To AGE
Waiting Final Action 
10/19/2022
METRONIDAZOLE 125MG/5ML, 60ML (BOT)
10/19/2022
10/23/2022
PO
3.5ml
Tid
Amoebiasis
Waiting Final Action 
10/20/2022
CIPROFLOXACIN 500MG (TAB)
10/20/2022
10/27/2022
ORAL
120mg/pptab
BID
Hypovolemic Shock Sec To AGE
Waiting Final Action 
10/28/2022
MUPIROCIN 2%, 15G (TUBE)
10/28/2022
11/04/2022
IV
Topical
Tid
Pcap D, T/c Parapneumonic Effusion Vs Tb
Waiting Final Action 
10/31/2022
CIPROFLOXACIN 500MG (TAB)
10/31/2022
11/07/2022
ORAL
120 Mg Pptab
12 Hrs
PCAP D
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: